The Influences of Nitric Oxide on Liver Ischemia-Reperfusion Injury by Erik Stoltenberg et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
The Influences of Nitric Oxide on  
Liver Ischemia-Reperfusion Injury 
Erik Stoltenberg, Alexander A. Vitin,  
Bradley E. Hansen and John D. Lang, Jr. 
University of Washington, Seattle,  
Department of Anesthesiology and Pain Medicine 
USA 
1. Introduction 
Ischemia-reperfusion injury (IRI) is a series of multifaceted cellular events that takes place 
on the resumption of oxygen delivery to the affected organ after a period of hypoxia. IRI 
occurs in the liver during procedures that are associated with vascular inflow obstruction 
followed by restoration of blood flow, particularly during orthotopic liver transplantation. 
IRI can result in major hepatocellular damage. 
In the last decade, nitric oxide (NO) has been shown to have various protective effects on 
cells during IRI. NO was first described as endothelium derived relaxing factor (EDRF), 
and it was described as being released from vascular endothelium to induce smooth 
muscle vasorelaxation. Since that time, much more has been elucidated about the role of 
NO in biological systems. NO has been demonstrated to inhibit oxidative stress, cytokine 
release, leukocyte endothelial adhesion and apoptosis (Phillips, Toledo, Lopez-Neblina, 
Anaya-Prado, & Toledo-Pereyra, 2009). On a cellular-signaling level, NO effects are 
mediated via redox-sensitive sites, and include: inhibition of protein kinase C, activation 
of tyrosine kinase, inactivation of NF-kB and activation of G proteins (Y. M. Kim, de Vera, 
Watkins, & Billiar, 1997). Previous studies have demonstrated that a reduction of NO 
during hepatic IRI, generally via a reduction in endothelial nitric oxide synthase (eNOS) 
activity, leads to liver injury (Köken & Inal, 1999). Inhaled NO or NO donor drugs are 
novel treatments that have been used clinically to attenuate liver IRI (Zaky, 
Siriussawakul, Tostenrud, Pauldine, & J. Lang, 2009). This review will discuss the 
pathophysiology of liver involvement during IRI and the clinical use of NO and its sister 
compounds in ameliorating the impact of liver IRI. 
2. An overview of hepatic ischemia reperfusion injury 
As noted above, the patholophysiology of IRI is multifactorial and involves a multitude of 
oxidative and cellular mechanisms. Briefly, hepatic IRI can be described as a two phase 
process with early (acute) and late (sub-acute) injury (Fan, Zwacka, & Engelhardt, 1999; 
Zwacka, Zhang, Zhou, Halldorson, & Engelhardt, 1998b). The distinction is particularly 
important because potential theraputic targets (i.e. methods of increasing NO in the hepatic  
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micro-envirnoment) may have different effects on these two phases. Early injury is mediated 
by a rapid change in the biochemical redox state of the tissue to a more oxidative one. It 
occurs within 5 minutes, and is not associated with leukocyte infiltration. Following the 
acute state is an increase in endothelial cell adhesion molecules, chemokines and cytokines. 
These molecules then herald the late phase characterized by a significant infiltration of 
polymorphonuclear neutrophils, further release of a reactive oxygen species (ROS) and 
extensive inflammation and tissue injury.  
NO plays a significant role in the acute phase of IRI, as this phase is associated with a rapid 
decrease in available NO. This decrease occurs either by depressed production by eNOS in 
sinusoidal endothelial cells (SECs), increased degradation by ROS, or both. The ROS 
implicated are chiefly O2•- (superoxide, see next paragraph), but also include hydrogen 
peroxide (H2O2). In the last few years, the implicated enzyme responsible for production of 
ROS has shifted from hepatoctye xanthine oxidase to NADPH oxidase in Kuppfer cells or 
mitochondrial sources of ROS (Hines & Grisham, 2011).  
The term “reactive oxygen species” in the context of hepatic IRI primarily refers to 
superoxide. Two studies that incorporated manganese superoxide dismutase (MnSOD) – an 
enzyme which degrades superoxide – into liver tissue showed attenuation of IRI (He et al., 
2006; Zwacka et al., 1998a). Therefore superoxide itself seems important in IRI. The 
mechanism by which superoxide imparts its damage is somewhat unclear, but it is known 
that membrane lipid peroxidation is associated with oxidative damage. Perhaps more 
importantly, damage by superoxide to mitochondrial membrane proteins and therefore ATP 
generating capacity and may a more important mechanism in IRI(Madesh & Hajnóczky, 
2001; Moon et al., 2008).  
3. Nitric oxide biochemistry 
NO is a highly reactive molecule with other free radical species and possesses an extremely 
short half-life (Rubbo, Darley-Usmar, & Freeman, 1996). NO is produced endogenously or 
delivered exogenously where it can react with a variety of cellular targets resulting in 
vasorelaxation, enhanced neuronal transmission, reduced apoptosis, inhibition of neutrophil 
aggregation and adhesion, and modulation of vascular smooth muscle proliferation.  
NO synthesis is dependent on the enzyme nitric oxide synthase (NOS). NOS catalyzes the 
net reaction: 
 L-Arginine + NADPH + O2 = Citrulline + Nitric oxide + NADP+ (1) 
(adapted from Alderton, Cooper, & Knowles, 2001) 
This complex enzyme system generates NO from the terminal nitrogen atom of L-arginine 
in the presence of NADPH and dioxygen. NOS binds flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN), heme, tetrahydrobiopterin (BH4) and calmodulin from  
L-arginine and oxygen by a family of three NO synthases (NOS), all of which are expressed 
in a variety of cell types.  
Three distinct isoforms are known: 1) Neuronal NOS (NOS I), is produced in central and 
peripheral nerves and is pivotal in neuronal transmission and cell-to-cell communication 
www.intechopen.com
 
The Influences of Nitric Oxide on Liver Ischemia-Reperfusion Injury 
 
59 
within the central nervous system. 2) Inducible NOS (NOS II is induced by an inflammatory 
stimulus such as a microbe (Parul Tripathi, Prashant Tripathi, Kashyap, & Singh, 2007). 
Unlike the other types of NOS (I and III), NOS II is not constitutive and is independent of 
calcium regulation. While NOS II is expressed by immune cells such as neutrophils and 
macrophages, it is also present in other cell lines including hepatocytes. Endothelial NOS 
(NOS III), is constitutively expressed by endothelial cells and is critical for the regulation of 
vascular function, more specifically vasorelaxation.  
 
(Modified, with permission from http://www.wiley.com/college/boyer) 
Fig. 1. Mechanisms of smooth muscle relaxation. NO diffuses across the muscle cell 
membrane and binds to guanylyl cyclase. Guanylyl cyclase catalyzes the synthesis of cyclic 
GMP from GTP. cGMP activates a cGMP-dependent protein kinase which stimulates the 
uptake of calcium by the endoplasmic reticulum of the muscle cell. The reduced levels of 
cytoplasmic calcium cause the muscle cell to relax. As a consequence of muscle cell relaxation, 
vasodilation occurs. PKG – protein kinase G 
The generation of NO leads to several actions that promote smooth muscle relaxation. First, 
activation of guanylate cyclase raises the level of intracellular cGMP which in turn inhibits 
the entry of calcium into the cell thereby inducing smooth muscle relaxation. Second,  
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activation of K+ channels leads to cellular hyperpolarization and relaxation. Finally, 
stimulation of cGMP-dependent protein kinase activates of myosin light chain phosphatase 
leading to dephosphorylation of myosin light chains resulting in smooth muscle relaxation. 
NOSs are related but encoded by distinct genes. Classically, the ability of NO to elicit 
vasorelaxation is due to its ability to increase intracellular levels of cyclic guanosine 
monophosphate (cGMP) through the activation of soluble guanylate cyclase (sGC). cGMP–
dependent protein kinases in turn decrease the sensitivity of myosin to calcium-induced 
contraction and lower intracellular calcium by activation of calcium-sensitive potassium 
channels and inhibits the release of calcium from the sacroplasmic reticulum. Mechanisms 
of smooth muscle relaxation are shown on Figure 1. 
4. Brief review of the pathophysiology of IRI 
 
Fig. 2. Multifaceted mechanism are involved in the causation of hepatic ischemia-reperfusion 
injury (IRI). Kupffer and endothelial cells produce cytokines and chemokines, recruiting 
neutrophils that further accentuate injury. EC, endothelial cell. NO (nitric oxide) is decreased 
as a result of IRI allowing for decreased perfusion and exaggerated injury (Massip-Salcedo, 
Roselló-Catafau, Prieto, Avíla, & Peralta, 2007). KC, Kuppfer cell. ATP, adenosine 
triphosphate. TNF, tumor necrosis factor. IL, interleukin. ICAM, intercellular adhesion 
molecule. PAF, platelet activation factor. LTB4, leukotrien B4. GMS-CSF, granulocyte 
macrophage colony stimulating factor. INF, interferon. ROS, reactive oxygen species. 
(Slighty modified with permission of Dr. Joan Rosello-Catafau, Barcelona, Spain) 
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During the ischemic phase, anaerobic metabolism ensues and produces an inadequate amount 
of high-energy phosphates which are fundamental to most cellular functions. Low levels of 
high-energy phosphates affects a myriad of cellular functions: homeostasis, signaling 
interactions, cellular proliferation and processing of the apoptotic death cycle. Adenosine 
triphosphate (ATP) depletion impairs the sodium/potassium ATPase (Na+/K+- ATPase) 
function, resulting in an impairment of the efflux of sodium from the cell. Additionally, toxic 
metabolites – which are generated during ischemia – attract free water into ischemic cells and 
organelles leading to the formation of cellular edema (Jennings, Shen, Hill, Ganote, & 
Herdson, 1978). If the ischemic insult lasts greater than 24 hours, it is likely that ATP-synthase 
activity becomes irreversible after blood restoration, leading to cellular necrosis, apoptosis or 
necroapoptosis (Sammut et al., 2000). Ischemia also causes an increased expression of adhesion 
molecules that leads to endothelial cell and neutrophil adhesion resulting in vascular studding 
and occlusion (Yadav et al., 1998). Furthermore, disequilibrium between NO and endothelin 
(ET) induces vasoconstriction and subsequent microcirculatory failure even though blood 
circulation has been re-established (Montalvo-Jave, Escalante-Tattersfield, Ortega-Salgado, 
Piña, & Geller, 2008). Reestablishment of blood flow will serve to amplify inflammation with 
consequent injury that is highly variable but dependent on numerous variables that include 
the extent of mediators produced (i.e. reactive oxygen species), the degree of endothelial and 
neutrophil adhesive responses and the degree of Kuppfer cell activation.  
5. Principal participants in liver IRI 
5.1 Sinusoidal endothelial cells (SEC) 
Injury to these cells is initiated during cold ischemia whereby Ca2+-ATPase results in the 
accumulation of intracellular calcium (Bigelow & Thomas, 1987). Following this event, a 
series of actions occur making the endothelium more susceptible to platelet adhesion and 
reduced sinusoidal flow. 
5.2 Kupffer cells 
Kupffer cells are crucial in liver injury orchestration. Metabolic alterations of these cells 
occur during no-flow ischemia leading to the formation of reactive oxygen species during 
early reperfusion (Jaeschke, Bautista, Spolarics, & Spitzer, 1991). Additionally, at the onset of 
reperfusion Kupffer cells undergo further activation by toll-like receptor 4 signaling and/or 
by complement. Subsequently, Kupffer cells release pro-inflammatory cytokines such as 
TNF-α and Interleukin-1 which themselves can perpetuate inflammatory injury by 
leukocyte activation. 
While major participants in the promotion of injury, during cold ischemia they undergo 
intracellular energetic bioenergetic perturbations that reduce ATP stores due to 
mitochondrial dysfunction and predispose these cells to injury during reperfusion (Kamiike 
et al., 1988).  
5.3 Leukocytes and lymphocytes 
As a result of IRI, cellular adhesion molecules (ie, intracellular adhesion molecule-1 or 
ICAM-1, vascular adhesion molecule-1 or VCAM-1), selectins and integrins are activated 
and upregulated on the surface of endothelial cells, neutrophils and platelets. The activated 
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neutrophils adhere to endothelial cells at the initial stages of reperfusion, and subsequently 
transmigrate the endothelium where they continue to orchestrate tissue injury. The 
accumulation of activated neutrophils contributes to microcirculatory disturbances both 
locally and remotely. Activated neutrophils release reactive oxygen species, specifically 
superoxide radical (O2-), proteases and various cytokines (Teoh & Farrell, 2003). Monocytes 
and macrophages are also activated shortly following reperfusion (Ysebaert et al., 2000). 
Recent studies propose an important role for lymphocytes, especially CD4+ T cells, in 
augmenting injury responses after IRI. However, lymphocytes may also play a protective 
role, but this is probably dependent on cell type and time course of injury (Ysebaert et al., 
2000).  
5.4 Reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
During periods of ischemia, ROS and RNS are generated which can promote intracellular 
damage. Due to electron transport chain alterations, mitochondrial dysfunction ensues 
leading to reductions in ATP production and with subsequent loss of inner membrane 
stability resulting in mitochondrial swelling and rupture. With the reintroduction of oxygen 
during reperfusion, ROS are produced due to reactions of oxygen introduced during 
reperfusion and possible xanthine oxidase (or mitochondrial sources of ROS). ROS serve to 
stimulate other cell lines including Kupffer cells to produce proinflammatory cytokines 
(Diesen & Kuo, 2011). The major ROS are hydroxyl radical (OH) and hydrogen 
peroxide.(H2O2). Reactions of ROS such as O2- with NO yield products such as 
peroxynitrite (ONOO-), a RNS which can be an extremely aggressive oxidant. 
5.5 Cytokines  
Cytokines play a vital role in IRI, both by inducing and sustaining the inflammatory 
response, and by modulating IRI severity. Tumor necrosis factor-alpha (TNF-α) and 
interleukin-1 (IL-1) are the two cytokines most commonly implicated in liver IRI. TNF-α is a 
pleiotropic cytokine generated by various different cell types in response to inflammatory 
and immunomodulatory stimuli. TNF-α modulates leukocyte chemotaxis and activation, 
and induces ROS production in Kupffer cells (Colletti et al., 1996). Additionally, IL-1 is 
known to promote production of ROS, induce TNF-α synthesis by Kupffer cells and induce 
neutrophil recruitment (Kato, Gabay, Okaya, & Lentsch, 2002). 
5.6 Complement 
The complement system also contributes significantly to IRI and is composed of 
approximately thirty soluble and membrane-bound proteins. This system can be stimulated 
in three pathways: (1) the antibody-dependent classical pathway, (2) the alternative 
pathway, or (3) the mannose-binding lectin pathway (Qin & Gao, 2006).  When activated, 
complement acts as a membrane-attacking complex that stimulates the production of 
proinflammatory cytokines and chemotactic agents. Furthermore, it can regulate adaptive 
immunity (Boros & Bromberg, 2006). 
6. The influence of endogenous NO on liver IRI 
Damage to the liver due to IRI is a culmination of inflammatory cross talk with the principal 
participants mentioned previously. Injury due to ischemia and reperfusion is the main cause  
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of liver injury in response to vascular clamping during hepatic procedures such as 
hepatectomy and liver transplantation. This insult on the liver results in disturbances of the 
sinusoidal microcirculation and the generation of a variety of mediators such as reactive 
oxygen species, cytokines, activation of chemokines and other cell signaling molecules 
previously mentioned. 
Hepatic IRI can cause severe hepatocellular injury that contributes to morbidity and 
mortality after liver surgery. As briefly mentioned previously, reductions of NO during 
liver IRI occur and are associated with increased liver injury (Köken & Inal, 1999). This is 
now appreciated to be due to decreases in NO steady-state production resulting from low 
concentrations of eNOS. This event coupled with NO inactivation due to reactions with 
abundant ROS, such as O2-, results in reduced NO bioavailability. The consequences of this 
reduced bioavailability include but are not exclusive to increased oxidative stress, increased 
apoptosis, increased leukocyte adhesion, increased microcirculatory tone, and perturbed 
mitochondrial function. Interestingly, restoration with of NO to more “physiologic” 
concentrations serves to diminish the liver ischemia injury via countering the adverse 
actions mentioned previously. Other studies have demonstrated findings that are consistent 
with the premise that eNOS is crucial for minimizing injury during liver IRI. For example, 
liver injury was less in wild type mice compared to eNOS knockouts (eNOS -/-), in addition 
to the findings that agents given to increase eNOS expression or donate NO afford greater 
liver IRI protection (Duranski et al., 2006; Katsumi, Nishikawa, Yamashita, & Hashida, 
2008). It is also well established that the NO concentrations during various inflammatory 
states are significantly increased by increased expression of inducible nitric oxide synthase 
or iNOS. However, the influence of iNOS and its true contribution in conferring liver 
protection deserves additional studies. In a rat model of liver IRI, iNOS expression was 
significantly increased as per increases in iNOS RNA at 1 and 5 hrs (Hur et al., 1999). This is 
consistent with other studies measuring iNOS expression of conditions of liver IRI. In a 
porcine model of IRI, intraportal injection of the selective iNOS inhibitor, aminoguanidine 
was demonstrated to decrease injury (M Isobe et al., 2000). In an intriguing study, NOS 
knockout mice (iNOS -/-) exposed to warm liver IRI demonstrated a much greater 
magnitude of injury compared to wild type mice. Interestingly, even though injury was 
greater in the iNOS knockout mice, little to no iNOS RNA was detectable in the wild type 
mice. It would appear for now, the true influence of iNOS’s influence on liver injury during 
IR remains unclear.  
A number of other endogenous NO-mediated mechanisms thought to confer protection 
have been published. For example, NO has been shown to inhibit caspase proteases via S-
nitrosylation, thereby inhibiting apoptosis (Maejima, Adachi, Morikawa, Ito, & Mitsuaki 
Isobe, 2005). This appears to be somewhat concentration dependent. Low physiological 
concentrations of NO may inhibit apoptosis. In contrast, higher concentrations may lead to 
the formation of toxic reactive nitrogen species such as ONOO- or reactive oxygen species 
which lead to cell necrosis and apoptosis (P. K. Kim, Zamora, Petrosko, & Billiar, 2001). 
Other published mechanisms of NO-mediated protection include inhibition of nuclear factor 
kappa B (Marshall, Hess, & Stamler, 2004), reversible inhibition of mitochondrial complex I, 
and decreased mitochondrial calcium accumulation (Burwell & Brookes, 2008). As to be 
expected, controversy exists concerning “if” and “how” NO exerts cellular protection. For 
instance, in a study by Jaeschke et al (Jaeschke et al., 1991), administration of a NO synthase 
inhibitor did not attenuate or accentuate liver injury during the initial reperfusion period.  
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Inhibition of NO was observed not to influence neutrophil migration to the injured sites. 
While this contradicts a number of other studies, based on their findings, the authors 
concluded that NO availability was unlikely to be involved in the post-ischemic oxidant 
stress and reperfusion injury (Jaeschke, Schini, & Farhood, 1992). Nevertheless, the majority 
of published literature has demonstrated the beneficial effects of NO during liver IRI. These 
conflicting results might be explained by the fact that the mechanism of NO-mediated 
protection varies depending on cell type, quantities supplied, laboratory methods applied, 
timing and duration of NO exposure. Here, we summarize some key studies studying 
endogenous NO and NOS in hepatic IRI Table 1.  
Species Experimental 
Methods 
Ischemic 
Time  
NO or NOS Effects Reference 
Pigs Aminoguanidine, 5 
min before ischemia 
120 min NO derived from iNOS, 
antioxidant 
(M Isobe et al., 
2000) 
Dogs FK 409, 30 min 
before ischemia 
and15 min before 
and to 45 min after 
reperfusion 
60 min NO, improve hepatic 
microcirculation 
(Aiba et al., 
2001)  
Rats L-arginine, 7 days 
before IRI 
60 min NO, antioxidant (Chattopadhy
ay et al., 2008) 
Rats L-NAME 60 min 
before ischemia  
30 min NO, antioxidant (Köken & Inal, 
1999) 
Mouse - Gadolinium 
chloride 24h before 
ischemia 
- L-nitroarginine  
(L-NAME) methyl 
ester 15 min prior to 
ischemia.  
45 min NO derived from eNOS, 
antioxidant, suppresses 
Kupffer cell function, 
regulated basal hepatic 
blood flow, but not affects 
blood flow after 
reperfusion, attenuated 
neutrophils infiltration. 
(Hines et al., 
2005) 
Rats - L-arginine or 
Sodium 
nitroprusside or  
L-Name prior to 
ischemia 
60 min NO, improve peripheral 
liver blood flow after 
reperfusion, cytoprotective
(Nilsson, 
Delbro, 
Wallin, & 
Friman, 2001) 
Male Rats - Arginine or  
L-NAME or  
8-bromo guanosine 
3′5′-cyclic 
monophosphate or 
rat atrial natriuretic 
peptide (ANP 1-28) 
30 min before 
ischemia 
45 min NO, antioxidant, 
antiproinflammatory 
cytokines, improves 
microcirculation by the 
cGMP pathway, Inhibit 
neutrophils infiltration 
and platelet aggregation.  
(Cottart et al., 
2003) 
Table 1. Effect of endogenous NO and NOS on liver IRI 
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7. Efficacy of exogenous NO, nitrite anion and NO donor administration in 
attenuating hepatic IRI 
7.1 Inhaled nitric oxide (iNO) 
Inhaled NO was approved by the U.S. Food and Drug Administration in December 1999, for 
the treatment of Persistent Hypertension of the newborn. Over the last decade, the primary 
advantage of iNO was seen to be its ability to selectively decrease pulmonary vascular 
resistance with minimal effects on systemic blood pressure; however, there is currently 
much interest in exploring its other benefits, including its antioxidant properties and its 
cytoprotective abilities (Zaky et al., 2009). In many animal studies, iNO decreased infarct 
size and left ventricular dysfunction after ischemia-reperfusion injury, increased coronary 
artery patency after thrombosis, increased blood flow in brain, kidney and peripheral 
vasculature, decreased leukocyte adhesion in bowel during ischemia reperfusion, and 
decreased platelet aggregation (McMahon & Doctor, 2006). Date et al reported the use of 
iNO in 15 out of 32 patients who suffered from immediate severe allograft dysfunction with 
iNO at 20 to 60 ppm. The mortality was significantly lower in the iNO group (7% and 24%, 
respectively). The gross benefits reported were that iNO improves oxygenation, decreases 
pulmonary artery pressure, shortens the period of postoperative mechanical ventilation, and 
reduces airway complications and mortality (Date et al., 1996). Likewise, a recent 
retrospective study also presented an improvement of overall respiratory functions. The 
authors encouraged the administration of iNO for the prevention and treatment of early 
graft failure in lung transplant recipients (Yerebakan, Ugurlucan, Bayraktar, Bethea, & 
Conte, 2009). Varadarajan et al were the first group to study the relationship between NO 
metabolism and IRI in human liver transplantation (Varadarajan et al., 2004). From their 
study, they concluded that reduced bioavailability of eNOS contributed to IRI one hour after 
portal reperfusion. On the other hand, iNOS did not contribute to early IRI after human 
liver transplantation. Clinical and mechanistic reports on therapeutic use of iNO 
demonstrating well beyond vascular relaxation, subsequently inactivated by oxy- 
ordeoxyhemoglobin in the red blood cells. iNO has various positive effects on 
extrapulmonary systems. However, how iNO mediates extrapulmonary effects remains 
unclear. Evidence supporting of stable forms of iNO is probably strongest for S-nitrosothiol 
(SNOs) and nitrite (McMahon & Doctor, 2006). In a prospective, blinded, placebo-controlled 
study, iNO at 80 ppm was administered to patients undergoing orthotropic liver 
transplantation (J. D. Lang et al., 2007). Many advantages were reported in the iNO group, 
including reduced platelet transfusion, an improvement in the rate at which liver function 
was restored post-transplantation on, and a decrease in the length of hospital stay. Most 
interesting was the finding of an approximated 75% reduction of hepatocellular apoptosis in 
patients treated with iNO (J. D. Lang et al., 2007). Possible biochemical intermediates of iNO 
including plasma and red blood cell nitrate, nitrite, S-nitrosothiols, C- or N-nitrosamines 
and red blood cell ferrous nitrosylhemoglobin. In this study, a detailed analysis indicated 
that the most likely candidate transducer of iNO on liver IRI was nitrite.  
7.2 iNO delivery systems 
An iNO delivery system should allow for constant and accurate measurements of NO and 
nitrogen dioxide [NO2] concentration in inspired gas as well as minimize the contact time 
between oxygen and NO in order to decrease the feasibility of producing high NO2 
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concentrations. The measurement of iNO and NO2 concentrations can be undertaken using 
chemiluminescence or electrochemical devices. There are some drawbacks of 
chemiluminescence devices such as cost, the need for a relatively high sample volume, noise 
and maintenance difficulties (Mupanemunda & Edwards, 1995). However, an 
electrochemical analyzer is relatively insensitive, and these measurements may be affected 
by pressure, humidity, temperature and the presence of other gases in the environment 
(Macrae et al., 2004). The delivery system should display the pressure of iNO in the cylinder 
and should have a backup power supply to avoid sudden discontinuation of iNO. Inhaled 
NO is usually supplied in nitrogen at various concentrations. The gas mixture concentration 
should be sampled downstream of the input port just proximal to the patient manifold. iNO 
also can be administered via nasal cannula, oxygen mask and oxygen hood (Ambalavanan, 
St John, Carlo, Bulger, & Philips, 2002). Finally, the exhausted gas should be scavenged by 
passing it through carbon and filters, soda lime or activated charcoal (Ambalavanan, El-
Ferzli, Roane, Johnson, & Carlo, 2009).  
7.3 Potential toxicities during inhalation 
In the presence of high concentrations of O2, NO oxidizes to nitrogen dioxide (NO2). NO2 
reacts with the alveolar lining fluid to form nitric acid. NO dissolves in the alveolar lining 
fluid reacts with O2- yielding OONO,- then decomposes into a hydroxyl anion (Pryor & 
Squadrito, 1995). Nitration of tyrosine residues of proteins is used as a marker of oxidative 
stress (Ischiropoulos, 1998). The rate at which NO is oxidized to NO2 depends on the square 
of NO concentration and fractional concentration of oxygen to which it is exposed. The 
Occupational and Health Administration recommend 5 ppm/8 hr/24 hour interval as the 
upper safe limit of human exposure (Fullerton & McIntyre, 1996). In order to protect against 
NO2 toxicity, iNO should be given with the least possible O2 concentration. Inhaled NO and 
NO2 concentrations should be monitored, exhaled gases should be scavenged and a soda 
lime canister should be placed in the inspiratory limb of the breathing circuit. 
7.4 Nitrite 
The simple molecule nitrite had been thought to be just an index of NO production for 
decades (Köken & Inal, 1999). Recently, a number of evidence suggests that nitrite is a pro-
mediator of NO homeostasis. Administration of nitrite at near physiological concentrations 
(<5 μg) leads to vasodilatation in animals and human studies (Fullerton & McIntyre, 1996). 
Gladwin et al observed that nitrite was metabolized across the peripheral circulation. In 
addition, nitrite caused an increase in peripheral forearm blood flow when 80 ppm iNO was 
administered (Shiva & Gladwin, 2009). Under distinct conditions such as hypoxia and 
acidosis, nitrite can be reduced to NO by a number of deoxyhemeproteins (hemoglobin, 
myoglobin, neuroglobin and cytoglobin), enzymes (cytochrome P450 and xanthine 
oxidoreductase), and components of the mitochondrial electron transport chain (Zaky et al., 
2009). Since nitrite can be converted back to NO during hypoxia nitrite therefore is expected 
to be utilized during ischemia reperfusion injury. Furthermore, nitrite shows more potential 
benefits than NO in terms of safety and ease of administration. In other words, nitrite 
concentrations administered need only a small dose in order to increase plasma and tissue 
nitrite level several-fold. Routes of administration are oral, intravenous injection or infusion, 
intraperitoneal, nebulizer or topical (Duranski et al., 2005). Nitrite has now been 
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demonstrated to have cytoprotective effects in animal models of ischemia reperfusion in 
organs. Duranski et al evaluated the effects of nitrite therapy in vivo murine models of 
hepatic and myocardial ischemia reperfusion injury and showed that nitrite was associated 
with cytoprotective effects. In the setting, nitrite reduced cardiac infarct size by 67% and 
limited elevations of liver enzymes in a dose-dependent manner. They also demonstrated 
that nitrite was reduced to NO regardless of eNOS and heme oxygenase-1 enzyme activities 
(Duranski et al., 2005). The exact mechanisms of how nitrite protects against the particular 
condition are being explored, but it appears that the benefit is mediated through the 
modulation of mitochondrial function by involving the posttranslational S-nitrosation of 
complex I to attenuate reperfusion oxygen radical generation and prevents cytochrome-C 
release (Shiva & Gladwin, 2009).  
7.5 NO donor drugs 
Since nitric oxide is not considered to be an ideal gas for the treatment of ischemia 
reperfusion injury, NO donor drugs are now being explored as an alternative to the parent 
compound. Novel drugs have been developed and used for the delivery of NO in order to 
compensate for the very short half-life of NO in vivo. However, there are only two types of 
NO donor drugs that are currently used clinically: organic nitrates and sodium 
nitroprusside. Organic nitrates are the most commonly used NO donor drugs treatment for 
coronary artery disease and congestive heart failure because the drugs produce clear clinical 
responses through their vasodilatory effects. Preparations of drugs include: slow release oral 
forms, ointments, transdermal patches, nebulizers and traditional intravenous forms. The 
main limitation of organic nitrates is the induction of drug tolerance with prolonged 
continuous use. NO release from nitroglycerin is likely via the enzyme mitochondrial 
aldehyde dehydrogenase (Yang, Chen, Kong, Xu, & Lou, 2007). On the other hand, the 
mechanism of NO release from sodium nitroprusside is more complex as demonstrated by   
Model Drugs Outcomes Reference 
Canine liver 
IRI 
FK-409,  Promote hepatic tissue blood flow, 
decrease serum Endothelin-1, 
cytoprotection 
(Aiba et al., 
2001) 
Isolated 
hepatocytes 
S-nitroso-N-
acetylpenicillamine 
(SNAP) 
- drug induced the expression of 
heat shock protein 70 mRNA and 
protein resulting in cytoprotection 
from TNFα 
(Y. M. Kim et 
al., 1997) 
Murine liver 
IRI 
Sodium nitroprusside - Promote hepatic tissue blood flow 
after reperfusion  
- cytoprotection 
(Nilsson et 
al., 2001) 
Murine liver 
IRI 
PEG-poly SNO-BSA, 
a sustained release of 
NO 
- Decreased neutrophils 
accumulation  
- Prevented the excessive 
production of iNOS 
(Katsumi et 
al., 2008) 
Murine liver 
IRI 
Macromolecule  
S-nitrosothiols 
Prevented hepatocellular injury (Katsumi et 
al., 2009) 
Table 2. Nitric oxide donors 
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Yang et al in a murine model of hepatic IRI. Sodium nitroprusside is thought to down-
regulate the mRNA expression of several enzymes related to hepatic injury (Katsumi et al., 
2008). Lastly, enhanced eNOS activation affords hepatoprotection during IRI and serves as 
yet another potential treatment option. Interestingly, liver preservation solutions 
supplemented with the agents trimetazidine (TMZ), 5-amino-4-imidazole carboxamide 
riboside (AICAR) or activated protein C (APC) have demonstrated allograft protection 
during conditions of cold ischemia (Katsumi, Nishikawa, Yasui, Yamashita, & Hashida, 
2009). Below, we summarize other novel NO donor drugs in Table 2. 
8. Conclusion 
Ischemia reperfusion injury is a well-defined threat to the liver during periods of 
interruption and restoration of oxygen delivery as occurs in certain procedures as hepatic 
resections and orthotopic liver transplantations. Relative NO deficiency is central in the 
pathogenesis of this injury. Replacing NO per se either by inhalation, nitrate anion or via 
donor drugs represents a novel means in ameliorating IRI. Further randomized controlled 
drugs are needed to evaluate this therapy in patients undergoing operative procedures 
causing IRI.  
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